As shown in Table 3, SGLT1 and HER2+ status still retained their power to predict shorter DFS (p = 0.001 and p < 0.001, respectively) and OS (p = 0.002 and p < 0.001, respectively) in breast cancer patients. This evidence concerns the gene SLC5A1 and breast cancer.